Tildrakizumab shows promising efficacy and safety in psoriatic arthritis
The results of a phase 2B study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate superior efficacy and comparable safety of tildrakizumab versus placebo in patients with psoriatic arthritis.
Jun 14, 2019
0
0